Beyond cholesterol reduction, the pleiotropic effects of statins: is their use in cancer prevention hype or hope?

References

• Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.Lancet 366(9493), 1267–1278 (2005).
   Google Scholar
• Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin. Biochem. 40(9–10), 575–584 (2007).
   Google Scholar
• Larosa JC. Pleiotropic effects of statins and their clinical significance. Am. J. Cardiol. 88(3), 291–293 (2001).
   Google Scholar
• Pedersen TR. Pleiotropic effects of statins: evidence against benefits beyond LDLcholesterol lowering. Am. J. Cardiovasc. Drugs 10(Suppl. 1), 10–17 (2010).
   Google Scholar
• Campbell MJ, Esserman LJ, Zhou Y et al. Breast cancer growth prevention by statins.Cancer Res. 66(17), 8707–8714 (2006).
   Google Scholar
• Kato S, Smalley S, Sadarangani A et al. Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase.J. Cell. Mol. Med. 14(5), 1180–1193 (2010).
   Google Scholar
• Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26(5), 883–891 (2005).
   Google Scholar
• Wong WW, Tan MM, Xia Z, Dimitroulakos J, Minden MD, Penn LZ. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin. Cancer Res. 7(7), 2067–2075 (2001).
   Google Scholar
• Shellman YG, Ribble D, Miller L et al. Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res. 15(2), 83–89 (2005).
   Google Scholar
• Ravnskov U, Mccully KS, Rosch PJ. The statin-low cholesterol-cancer conundrum.Q JM 105(4), 383–388 (2012).
   Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N. Engl. J. Med. 335(14), 1001–1009 (1996).
   Google Scholar
• Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360(9346), 1623–1630 (2002).
   Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333(20), 1301–1307 (1995).
   Google Scholar
• Ford I, Murray H, Packard CJ et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N. Engl. J. Med. 357(15), 1477–1486 (2007).
   Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753), 1670–1681 (2010).
   Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration, Emberson JR, Kearney PM et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PloS ONE 7(1), e29849 (2012).
   Google Scholar
• Rossebo AB, Pedersen TR, Boman K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 359(13), 1343–1356 (2008).
   Google Scholar
• Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebocontrolled trial. Lancet 377(9784), 2181–2192 (2011).
   Google Scholar
• Zeichner S, Mihos CG, Santana O. The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: a comprehensive review. J. Cancer Res. Ther. 8(2), 176–183 (2012).
   Google Scholar
• Osmak M. Statins and cancer: current and future prospects. Cancer Lett. 324(1), 1–12 (2012).
   Google Scholar
• Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 367(19), 1792–1802 (2012).
   Google Scholar
• Frohlich GM, Rufibach K, Enseleit F et al. Statins and the risk of cancer after heart transplantation. Circulation 126(4), 440–447 (2012).
   Google Scholar
• Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359(21), 2195–2207 (2008).
   Google Scholar
• Singh S, Singh AG, Singh PP, Murad MH, Iyer PG. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. pii: S1542-3565(13)00094-3 (2013).
   Google Scholar
• Chiu HF, Ho SC, Chang CC, Wu TN, Yang CY. Statins are associated with a reduced risk of gastric cancer: a population-based casecontrol study. Am. J. Gastroenterol. 106(12), 2098–2103 (2011).
   Google Scholar
• Lee J, Lee SH, Hur KY, Woo SY, Kim SW, Kang WK. Statins and the risk of gastric cancer in diabetes patients. BMC Cancer 12, 596 (2012).
   Google Scholar
• Hachem C, Morgan R, Johnson M, Kuebeler M, El-Serag H. Statins and the risk of colorectal carcinoma: a nested case–control study in veterans with diabetes. Am. J. Gastroenterol. 104(5), 1241–1248 (2009).
   Google Scholar
• Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis.Gastroenterology pii: S0016-5085(12)01496-5 (2012).
   Google Scholar
• Bansal D, Undela K, D’Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS ONE 7(10), e46691 (2012).
   Google Scholar
• Marcella SW, David A, Ohman-Strickland PA, Carson J, Rhoads GG. Statin use and fatal prostate cancer: a matched case–control study. Cancer 118(16), 4046–4052 (2012).
   Google Scholar
• Caner M, Sonmez B, Kurnaz O et al. Atorvastatin has cardiac safety at intensive cholesterol-reducing protocols for long term, yet its cancer-treatment doses with chemotherapy may cause cardiomyopathy even under coenzyme-Q10 protection. Cell Biochem. Funct. 25(4), 463–472 (2007).
   Google Scholar
• Jakobisiak M, Golab J. Statins can modulate effectiveness of antitumor therapeutic modalities. Med. Res. Rev. 30(1), 102–135 (2010).
   Google Scholar
• Kawata S, Yamasaki E, Nagase T et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer 84(7), 886–891 (2001).
   Google Scholar
• Kornblau SM, Banker DE, Stirewalt D et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C. A Phase 1 study. Blood 109(7), 2999–3006 (2007).
   Google Scholar
• Lopez-Aguilar E, Sepulveda-Vildosola AC, Betanzos-Cabrera Y et al. Phase II study of metronomic chemotherapy with thalidomide, carboplatin-vincristine-fluvastatin in the treatment of brain stem tumors in children.Arch. Med. Res. 39(7), 655–662 (2008).
   Google Scholar
• Konings IR, van Der Gaast A, van Der Wijk LJ, de Jongh FE, Eskens FA, Sleijfer S. The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised Phase II trial. Eur. J. Cancer 46(18), 3200–3204 (2010).
   Google Scholar
• Han JY, Lim KY, Yu SY, Yun T, Kim HT, Lee JS. A Phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensivedisease small cell lung cancer. Cancer 117(10), 2178–2185 (2011).
   Google Scholar
• Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J. Am. Coll. Cardiol. 60(23), 2384–2390 (2012).
   Google Scholar
• Glynn RJ, Danielson E, Fonseca FA et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism.N. Engl. J. Med. 360(18), 1851–1861 (2009).
   Google Scholar
• Novack V, Macfadyen J, Malhotra A, Almog Y, Glynn RJ, Ridker PM. The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. CMAJ 184(7), e367–e372 (2012).
   Google Scholar